This trial is testing a new combination cancer treatment of selinexor and R-GDP, to see if it is more effective and has fewer side effects than the standard R-GDP treatment.
2 Primary · 14 Secondary · Reporting Duration: From date of initial randomization until death (maximum of 5 years from randomization)
Active Control
Experimental Treatment
Non-Treatment Group
501 Total Participants · 6 Treatment Groups
Primary Treatment: Selinexor (combination therapy) · Has Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: